(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, 4th May, 2023

ORDER

S.O. 2123(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

SI. No	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Amoxycillin and Potassium Clavulanate Oral Suspension (Combi pack with Sterile Water for Reconstitution of Dry Syrup)	Each combi pack contains: A. Amoxycillin and Potassium Clavulanate Oral suspension IP Composition: Each 5ml of reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg B. 2 Ampoules of sterile water for reconstitution of dry syrup each ampoule contains: sterile water for injection IP 25ml	Each Combi Pack	M/s Malik Lifesciences Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited	162.1 1
2	Paracetamol, Phenylephrine Hydrochloride & Chlorpheniram ine maleate Tablets	Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 10mg Chlorpheniramine maleate IP 2mg	1 Tablet	M/s East African (India) Overseas / M/s Alkem Laboratories Ltd.	4.42

SI. No	Name of the Formulation /	Strength	Unit	Manufacturer & Marketing	Retail Price
. (4)	Brand Name	(2)	(4)	Company	(Rs.)
3	(2) Amoxycillin & Potassium Clavulanate Tablets IP	(3) Each film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 875mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg	1 Tablet	M/s Theon Pharmaceuticals Limited / M/s FDC Limited	33.92
4	Ofloxacin and Betamethason e Sodium Phosphat Eye / Ear Drops	Composition: Ofloxacin IP 0.3% w/v Betamethasone Sodium Phosphate IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative)	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	1.45
5	Tranexamic Acid and Etamsylate Tablets	Each film coated tablet contains: Etamsylate BP 250mg Tranexamic Acid IP 500mg.	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Torrent Pharmaceuticals Ltd.	23.37
6	Aceclofenac and Paracetamol Tablets	Each film coated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg	1 Tablet	M/s Aagya Biotech Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd.	4.83
7	Calcium, Vitamin D3, Mecobalamin, L-Methylfolate Calcium & Pyridoxal-5- Phosphate Tablets	Each film coated tablet contains: Calcium Carbonate IP 1250mg eq. to Elemntal Calcium 500mg Vitamin D3 IP 2000 IU Mecobalamin IP 1500mcg L-Methylfolate Calcium 1mg Pyridoxal-5-Phosphate 20mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd.	18.36
8	Itraconazole Capsules 65mg (Supra- Bioavailable Formulation)	Each hard gelatin capsule contains: Itraconazole BP 65mg	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.	11.94
9	Chlorhexidine gluconate, Metronidazole and Lignocaine	Composition: Chlorhexidine gluconate solution IP eq. to Chlorhexadine 1 % w/w, Metronidazole Bezoate	1 GM	M/s Alaina Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	3.75

SI. No	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Hydrochloride Gel	IP eq. to Metronidazole 1% w/w Lignocaine Hydrochloride IP 2% w/w	. ,		
10	Itraconazole Capsules 65mg (Supra- Bioavailable Formulation)	Each hard gelatin capsule contains:Itraconazole BP 65mg	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited	11.94
11	Itraconazole Capsules 130mg (Supra- Bioavailable Formulation)	Each hard gelatin capsule contains: Itraconazole BP 130mg	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited	20.72
12	Pantoprazole (EC) and Levosulpiride (SR) Capsules	Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg (as enteric coated pellets) Levosulpiride 75mg (As sustained release pellets)	1 Capsule	M/s Theon Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd.	16.15
13	Linezolid Infusion	Each 100ml contains: Linezolid IP 200mg Dextrose (Anhydrous) 5% w/v Water for Injection IP	1 ml	M/s AXA Parenterals Ltd. / M/s Themis Medicare Limited	1.36
14	Bisoprolol Fumarate and Amlodipine Tablets	Each film coated tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg	1 Tablet	M/s Swiss Garniers Biotech Pvt. Ltd. / M/s Zydus Healthcare Limited	8.34
15	Alpha Lipoic Acid + Mecobalamin + Myo-Inositol + Folic Acid + Pyridoxine Hydrochloride + Chromium Picolinate and Benfortiamine Tablets	Each film coated table contains: Alpha Lipoic Acid IP 200mg Mecobalamin IP 1500mcg Myo-Inositol IP 100mg Folic Acid IP 1.5mg Pyridoxine Hydrochloride IP 3mg Chromium Picolinate IP eq. to Elemental	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zydus Healthcare Limited	22.86

SI. No	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
		chromium 200mcg			
		Benfortiamine 200mg			

Note:

- (a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

PN/244/112/2023/F

F. No. 8(112)/2023/D.P./NPPA-Div.-II

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 11th May, 2023

CORRIGENDUM

S.O. 2167(E). — In the National Pharmaceutical Pricing Authority's notification S.O. 2123(E), dated 4th May 2023 relating to fixation of retail price, published in the Gazette of India, Extraordinary, the Entry at Sl. No. 04 of the Table, both in Hindi & English version, be read as follows:

Instead of

SI. No	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
4	Ofloxacin and Betamethason e Sodium Phosphat Eye / Ear Drops	Composition: Ofloxacin IP 0.3% w/v Betamethasone Sodium Phosphate IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative)	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	1.45

Read as

SI. No	Name of the Formulation /	Strength	Unit	Manufacturer & Marketing	Retail Price
	Brand Name			Company	(Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
4	Ofloxacin and Betamethason e Sodium Phosphat Eye / Ear Drops	Composition: Ofloxacin IP 0.3% w/v Betamethasone Sodium Phosphate IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative)	1 ml	M/s Skymap Healthcare Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	1.45

All the notes and other contents mentioned in the original order S.O. 2123(E), dated 4th May 2023 shall remain same.

PN/244/112/2023/F

F. No. 8(112)/2023/D.P./NPPA-Div.-II

(Mahaveer Saini) Deputy Director